Vosoritide improves tibial bowing in infants and toddlers with achondroplasia

Klane White¹, Melita Irving², Christine Rivat³, Claire Milligan³, Sue Lawrinson³, Alice Huntsman Labed³, Ian Sabir³, Jonathan Day³, Ravi Savarirayan⁴

¹Children's Hospital Colorado, Aurora, CO, USA; ²Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Research Institute, Royal Children's Hospital, and University of Melbourne, Parkville, Victoria, Australia


Introduction


- Vosoritide, an analog of C-type natriuretic peptide, is approved for use in children with achondroplasia (ACH)¹
- By stimulating endochondral bone growth, vosoritide positively impacts body proportionality and quality of life^{2,3}
- Tibial bowing is a common orthopedic complication of ACH, with an incidence of 40%–70%.⁴ Tibial bowing is a cause of pain and impaired function for children with ACH and a common reason for surgical intervention, with ~25% requiring surgery⁵
- Here, we assess the impact of vosoritide treatment on the degree of bowing present in the study population

Objective

 To assess the impact of vosoritide treatment on tibial bowing in children with ACH who began treatment aged <5 years

Study design





Study 111-208 (NCT03989947) Ongoing open-label extension study, with patients receiving




Data shown are based on 3-year observation.

aParticipants received 30 μg/kg of vosoritide until 2 years of age, then switched to a dose of 15 μg/kg. Vosoritide was administered as a single daily subcutaneous injection. ACH, achondroplasia.

Tibial bowing analysis

- Image acquisition was standardized across the sites, and X-rays were centrally read by independent radiologists to minimize variability in measurement
- X-rays were taken at baseline and week 52 for the 111-206 study and every 2 years for the 111-208 study
- Degree of tibial bowing was observed radiographically as the linear intersections derived from the upper and lower physeal plates and the mid-shaft of the tibia
- Magnitude of change in tibial bowing was quantified as least squares mean change from baseline, applying an analysis of covariance model, and reported in degrees



Results

Participants

- The 111-206 total population included 11 sentinel participants who received vosoritide and 64 participants randomized 1:1 to vosoritide or placebo (**Table 1**)
- The 73 participants who completed 111-206 enrolled in 111-208, the open-label long-term extension
- For the overall 111-206 population, tibial bowing was present in both the left and right legs at baseline


Table 1. Baseline characteristics and growth parameters of all vosoritide-treated participants and those randomly assigned to placebo from 111-2066

Characteristic	Total population	
	Vosoritide (n = 43)	Placebo (n = 32)
Age on day 1, ^a months	24.47 (17.66)	27.82 (19.25)
Sex		
Male	25 (58.1%)	13 (40.6%)
Female	18 (41.9%)	19 (59.4%)
Race		
White	29 (67.4%)	25 (78.1%)
Asian	11 (25.6%)	6 (18.8%)
Other ^b	3 (7.0%)	1 (3.1%)
Hispanic or Latino ethnicity	3 (7.0%)	3 (9.4%)
Height Z score ^c	-3.88(0.90)	-4.28(1.48)
Baseline tibial bowing angle, degrees		
Right leg	11.81 (6.49), n = 42	11.41 (7.44), n = 32
Left leg	9.98 (7.14), n = 42	12.59 (7.98), n = 32

^aDay 1 of treatment. ^bOther includes multiple races and Native Hawaiian or Other Pacific Islander. ^cZ scores were derived using age-specific and sex-specific reference data (means and SD) for average-stature children according to the US Centers for Disease Control and Prevention. ⁷ SD, standard deviation.


Tibial bowing results

Figure 1. LSM difference between vosoritide and placebo in change from baseline at year 1



• After 1 year of treatment, vosoritide improved tibial bowing angle from baseline compared with placebo in both legs

Figure 2. Tibial bowing over time for participants in the 111-206 active arm receiving vosoritide for up to 3 years



 In 3 years of vosoritide treatment for those who entered study 111-208, tibial bowing angle continued to decrease in both legs

Conclusions

- Treatment with vosoritide significantly improved tibial bowing for children with ACH <5 years old at the start of treatment compared with placebo after 1 year, with continued improvement over 3 years
- These results suggest vosoritide treatment from an early age provides growth increases that positively impact complications of ACH

References

1. Voxzogo (vosoritide). Prescribing information. BioMarin Pharmaceutical Inc.; 2021. 2. Savarirayan R, et al. *Genet Med.* 2021;23:2443–7. 3. Savarirayan R, et al. *Genet Med.* 2024;26(12):101274. 4. Savarirayan R, et al. *Nat Rev Endocrinol.* 18(3):173–89. 5. Nahm NJ, et al. *Orphanet J Rare Dis.* 2023;18(1):139. 6. Savarirayan R, et al. *Lancet Child Adolesc Health.* 2024;8(1):40–50. 7. Coghlan RF, et al. *Sci Transl Med.* 2017;9:eaan4669.

Acknowledgements

Medical writing support was provided by Sanna Abbasi, PhD, of AlphaBioCom, a Red Nucleus company, and funded by BioMarin Pharmaceutical Inc.

Disclosures

KW has received grant funding from Ascendis, BioMarin Pharmaceutical Inc., and Ultragenyx; royalties from UptoDate.com, and has received consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from BioMarin Pharmaceutical Inc. MI has received honoraria from BioMarin Pharmaceutical Inc., for speaking, for participating in advisory board meetings, and as a member of the vosoritide experts steering committee. CR, CM, SL, AHL, IS, and JD are employees of BioMarin (UK) Ltd, London, UK. RS has received consulting fees from Ascendis and BridgeBio Pharma and consulting fees and grants from BioMarin Pharmaceutical Inc.

